{"DataElement":{"publicId":"3136597","version":"1","preferredName":"Disease or Disorder Chemosensitivity Type","preferredDefinition":"A description of the sensitivity of the disease to chemotherapy.","longName":"3136596v1.0:2961482v1.0","context":"NHLBI","contextVersion":"1","DataElementConcept":{"publicId":"3136596","version":"1","preferredName":"Disease or Disorder Chemosensitivity","preferredDefinition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function._Sensitivity of a malignancy to administration of chemotherapy, usually defined as the achievement of a partial response or better.","longName":"2404658v1.0:2954712v1.0","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"2404658","version":"1","preferredName":"Diseases and Disorders","preferredDefinition":"A definite pathologic process with a characteristic set of signs and symptoms. It may affect the whole body or any of its parts, and its etiology, pathology, and prognosis may be known or unknown.","longName":"C2991","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Disease or Disorder","conceptCode":"C2991","definition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"005AD6E5-0651-6A35-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-09-09","endDate":null,"createdBy":"PWEST","dateCreated":"2005-09-09","modifiedBy":"ONEDATA","dateModified":"2005-09-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2954712","version":"1","preferredName":"Chemosensitivity","preferredDefinition":"Sensitivity of a malignancy to administration of chemotherapy, usually defined as the achievement of a partial response or better.","longName":"C71488","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chemosensitivity","conceptCode":"C71488","definition":"Sensitivity of a malignancy to administration of chemotherapy, usually defined as the achievement of a partial response or better.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"765EB49C-413A-F476-E040-BB89AD43561B","latestVersionIndicator":"Yes","beginDate":"2009-10-20","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2009-10-20","modifiedBy":"ONEDATA","dateModified":"2009-10-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8FECF977-4952-7128-E040-BB89AD437E67","latestVersionIndicator":"Yes","beginDate":"2010-09-10","endDate":null,"createdBy":"ZHANGW","dateCreated":"2010-09-10","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2961482","version":"1","preferredName":"Solid Tumor Chemosensitivity Type","preferredDefinition":"A benign or malignant neoplasm arising from tissues that do not include fluid areas.  Representative examples include epithelial neoplasms (e.g. lung carcinoma, prostate carcinoma, breast carcinoma, colon carcinoma), and neoplasms arising from the soft tissues and bones (e.g. leiomyosarcoma, liposarcoma, chondrosarcoma, osteosarcoma).  Neoplasms originating from the blood or bone marrow (leukemias and myeloproliferative disorders) are not considered solid tumors._Sensitivity of a malignancy to administration of chemotherapy, usually defined as the achievement of a partial response or better._Something distinguishable as an identifiable class based on common qualities.","longName":"S_TUMR_CHEMO_TP","context":"NHLBI","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"100","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Sensitive","valueDescription":"Sensitive","ValueMeaning":{"publicId":"3131006","version":"1","preferredName":"Sensitive","longName":"3131006","preferredDefinition":"Greater than or equal to 50 percent reduction in bidimensional diameter of all disease sites with no new sites of disease.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E310A94-443C-DD37-E040-BB89AD4337F5","latestVersionIndicator":"Yes","beginDate":"2010-08-19","endDate":null,"createdBy":"ZHANGW","dateCreated":"2010-08-19","modifiedBy":"ONEDATA","dateModified":"2010-08-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E310A94-4454-DD37-E040-BB89AD4337F5","beginDate":"2009-11-18","endDate":null,"createdBy":"ZHANGW","dateCreated":"2010-08-19","modifiedBy":"ONEDATA","dateModified":"2010-08-19","deletedIndicator":"No"},{"value":"Not assessed, or chemotherapy less than 2 cycles","valueDescription":"Not assessed, or chemotherapy less than 2 cycles","ValueMeaning":{"publicId":"3131004","version":"1","preferredName":"Not assessed, or chemotherapy less than 2 cycles","longName":"3131004","preferredDefinition":"Not assessed, or chemotherapy less than 2 cycles","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E310A94-43F6-DD37-E040-BB89AD4337F5","latestVersionIndicator":"Yes","beginDate":"2010-08-19","endDate":null,"createdBy":"ZHANGW","dateCreated":"2010-08-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E310A94-440F-DD37-E040-BB89AD4337F5","beginDate":"2009-11-18","endDate":null,"createdBy":"ZHANGW","dateCreated":"2010-08-19","modifiedBy":"ONEDATA","dateModified":"2010-08-19","deletedIndicator":"No"},{"value":"Resistant","valueDescription":"Resistant","ValueMeaning":{"publicId":"3131005","version":"1","preferredName":"Resistant","longName":"3131005","preferredDefinition":"Less than 50 percent reduction in diameter of all disease sites or development of new disease sites.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E310A94-4419-DD37-E040-BB89AD4337F5","latestVersionIndicator":"Yes","beginDate":"2010-08-19","endDate":null,"createdBy":"ZHANGW","dateCreated":"2010-08-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E310A94-4432-DD37-E040-BB89AD4337F5","beginDate":"2009-11-18","endDate":null,"createdBy":"ZHANGW","dateCreated":"2010-08-19","modifiedBy":"ONEDATA","dateModified":"2010-08-19","deletedIndicator":"No"},{"value":"Untreated, or treated greater than 6 months prior to transplant","valueDescription":"Untreated, or treated greater than 6 months prior to transplant","ValueMeaning":{"publicId":"3131022","version":"1","preferredName":"Untreated, or treated greater than 6 months prior to transplant","longName":"3131022","preferredDefinition":"Untreated, or treated greater than 6 months prior to transplant","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E310A94-448B-DD37-E040-BB89AD4337F5","latestVersionIndicator":"Yes","beginDate":"2010-08-19","endDate":null,"createdBy":"ZHANGW","dateCreated":"2010-08-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E310A94-44A4-DD37-E040-BB89AD4337F5","beginDate":"2009-11-18","endDate":null,"createdBy":"ZHANGW","dateCreated":"2010-08-19","modifiedBy":"ONEDATA","dateModified":"2010-08-19","deletedIndicator":"No"},{"value":"Unknown","valueDescription":"Unknown","ValueMeaning":{"publicId":"2575365","version":"1","preferredName":"Unknown","longName":"2575365","preferredDefinition":"Not known, not observed, not recorded, or refused.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Unknown","conceptCode":"C17998","definition":"Not known, observed, recorded; or reported as unknown by the data contributor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F372-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-15","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"MMADDINENI","dateModified":"2024-01-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"87982A1E-4C54-FAA5-E040-BB89AD435B6C","beginDate":"2010-01-13","endDate":null,"createdBy":"ZHANGW","dateCreated":"2010-05-27","modifiedBy":"ONEDATA","dateModified":"2010-05-27","deletedIndicator":"No"},{"value":"Untreated","valueDescription":"Negation Therapy","ValueMeaning":{"publicId":"3061597","version":"1","preferredName":"Negation Therapy","longName":"3061597","preferredDefinition":"An operation in which a term denies or inverts the meaning of another term or construction.: An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Negation","conceptCode":"C25594","definition":"An operation in which a term denies or inverts the meaning of another term or construction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Therapy","conceptCode":"C15368","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"84902434-A37B-9A05-E040-BB89AD431C3A","latestVersionIndicator":"Yes","beginDate":"2010-04-19","endDate":null,"createdBy":"MOROZOFA","dateCreated":"2010-04-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"87982A1E-4C68-FAA5-E040-BB89AD435B6C","beginDate":"2010-04-19","endDate":null,"createdBy":"ZHANGW","dateCreated":"2010-05-27","modifiedBy":"ONEDATA","dateModified":"2010-05-27","deletedIndicator":"No"},{"value":"Refractory","valueDescription":"Refractory","ValueMeaning":{"publicId":"3117283","version":"1","preferredName":"Refractory","longName":"3117283","preferredDefinition":"Progression of disease within 4 weeks of last Cisplatin dose","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8A6D16BF-6B57-B018-E040-BB89AD432A62","latestVersionIndicator":"Yes","beginDate":"2010-07-02","endDate":null,"createdBy":"ZHANGW","dateCreated":"2010-07-02","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8A6D16BF-6B70-B018-E040-BB89AD432A62","beginDate":"2010-01-13","endDate":null,"createdBy":"ZHANGW","dateCreated":"2010-07-02","modifiedBy":"ONEDATA","dateModified":"2010-07-02","deletedIndicator":"No"},{"value":"Chemotherapy was only given as adjuvant to the primary surgery or radiation therapy","valueDescription":"Chemotherapy was only given as adjuvant to the primary surgery or radiation therapy","ValueMeaning":{"publicId":"3361678","version":"1","preferredName":"Chemotherapy was only given as adjuvant to the primary surgery or radiation therapy","longName":"3361678","preferredDefinition":"Chemotherapy was only given as adjuvant to the primary surgery or radiation therapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B736A379-70C1-37F3-E040-BB89AD4345C4","latestVersionIndicator":"Yes","beginDate":"2012-01-23","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2012-01-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B736A379-70DA-37F3-E040-BB89AD4345C4","beginDate":"2012-01-23","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2012-01-23","modifiedBy":"ONEDATA","dateModified":"2012-01-23","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2435022","version":"1","preferredName":"Disease, Disorder or Finding","preferredDefinition":"Specification of human conditions relevant to cancer. This includes observations, test results, history, and other concepts relevant to characterization of human cancer-related conditions. Non-neoplastic conditions of interest are also included.","longName":"C7057","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0741B16D-87D9-26CD-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2961481","version":"1","preferredName":"Solid Neoplasm Chemosensitivity Type","preferredDefinition":"Cancer of body tissues other than blood, bone marrow, or the lymphatic system.:Sensitivity of a malignancy to administration of chemotherapy, usually defined as the achievement of a partial response or better.:Type; a subdivision of a particular kind of thing.","longName":"C9292:C71488:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Solid Neoplasm","conceptCode":"C9292","definition":"A benign or malignant neoplasm arising from tissues that do not include fluid areas.  Representative examples include epithelial neoplasms (e.g. lung carcinoma, prostate carcinoma, breast carcinoma, colon carcinoma), and neoplasms arising from the soft tissues and bones (e.g. leiomyosarcoma, liposarcoma, chondrosarcoma, osteosarcoma).  Neoplasms originating from the blood or bone marrow (leukemias and myeloproliferative disorders) are not considered solid tumors.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Chemosensitivity","conceptCode":"C71488","definition":"Sensitivity of a malignancy to administration of chemotherapy, usually defined as the achievement of a partial response or better.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"78AC8450-53B6-BCA8-E040-BB89AD4336B8","latestVersionIndicator":"Yes","beginDate":"2009-11-18","endDate":null,"createdBy":"ZHANGW","dateCreated":"2009-11-18","modifiedBy":"ONEDATA","dateModified":"2009-11-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"78AC8450-53C7-BCA8-E040-BB89AD4336B8","latestVersionIndicator":"Yes","beginDate":"2009-11-18","endDate":null,"createdBy":"ZHANGW","dateCreated":"2009-11-18","modifiedBy":"KUMMEROA","dateModified":"2012-06-18","changeDescription":".Added alt defs for form 2022. AK 6/18/12","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2695319","version":"1","longName":"NMDP: CDEs to review","context":"NHLBI","ClassificationSchemeItems":[{"publicId":"2964893","version":"1","longName":"2025r1: Central Nervous System Tumor Pre-HSCT Data","context":"NHLBI"},{"publicId":"2964891","version":"1","longName":"2020r1: Breast Cancer Pre-HSCT Data","context":"NHLBI"},{"publicId":"2964890","version":"1","longName":"2018r1: Lymphoma Pre-HSCT Data","context":"NHLBI"},{"publicId":"2964899","version":"1","longName":"2022r1: Testicular / Germ Cell Cancer Pre-HSCT Data","context":"NHLBI"}]},{"publicId":"3553940","version":"1","longName":"BRIDG","context":"NHLBI","ClassificationSchemeItems":[{"publicId":"4133055","version":"1","longName":"Version 3.2","context":"NHLBI"}]},{"publicId":"6685474","version":"1","longName":"Artificial Neural Network Algorithm for BRIDG Mapping","context":"NCIP","ClassificationSchemeItems":[{"publicId":"6685476","version":"1","longName":"Training Set","context":"NCIP"}]}],"AlternateNames":[{"name":"tc_base_sens_chemo_kn","type":"NMDP_FN","context":"NHLBI"},{"name":"bc_base_sens_chemo_kn","type":"NMDP_FN","context":"NHLBI"},{"name":"lym_base_prep_chem_sentvy","type":"NMDP_FN","context":"NHLBI"},{"name":"cns_base_sens_chemo_kn","type":"NMDP_FN","context":"NHLBI"},{"name":"PerformedClinicalInterpretation:value ","type":"HCT_BRIDG","context":"NHLBI"},{"name":"NRG","type":"USED_BY","context":"NRG"}],"ReferenceDocuments":[{"name":"What was the sensitivity of t","type":"Preferred Question Text","description":"What was the sensitivity of the disease to chemotherapy?","url":null,"context":"NHLBI"},{"name":"Indicate the sensitivity of the testicular carcinoma to any chemotherapeutic agent administered:","type":"Alternate Question Text","description":"Indicate the sensitivity of the testicular carcinoma to any chemotherapeutic agent administered:","url":null,"context":"NHLBI"},{"name":"BRIDG mapping path for CDE:3136597","type":"BRIDG Mapping Path","description":"PerformedClinicalInterpretation.value WHERE PerformedClinicalInterpretation > PerformedObservation > DefinedObservation.nameCode = \"assess sensitivity\" AND PerformedObservation > AssessActivityRelationship > PerformedSubstanceAdministration > DefinedSubstanceAdministration.nameCode = \"Administer chemotherapy\"","url":null,"context":"NHLBI"},{"name":"What was the sensitivity of the central nervous system tumor to chemotherapy?","type":"Alternate Question Text","description":"What was the sensitivity of the central nervous system tumor to chemotherapy?","url":null,"context":"NHLBI"},{"name":"Specify the sensitivity of myeloma to chemotherapy","type":"Alternate Question Text","description":"Specify the sensitivity of myeloma to chemotherapy","url":null,"context":"NHLBI"},{"name":"NRG_CRF text","type":"Alternate Question Text","description":"Does the patient have recurrent platinum-resistant or refractory disease (defined as disease that has progressed while receiving platinum or had recurrence within 6 months of the last receipt of platinum based chemotherapy)?","url":null,"context":"NRG"},{"name":"NRG_CRF text 2","type":"Alternate Question Text","description":"Does the patient have recurrent platinum-resistant or refractory disease (defined as disease that has progressed by imaging while receiving platinum or had recurrence within 6 months of the last receipt of platinum based chemotherapy)?","url":null,"context":"NRG"}],"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8FED2D60-41BD-8CE0-E040-BB89AD4316F4","latestVersionIndicator":"Yes","beginDate":"2010-09-10","endDate":null,"createdBy":"ZHANGW","dateCreated":"2010-09-10","modifiedBy":"KUMMEROA","dateModified":"2021-08-05","changeDescription":". 3/21/12mn-added cs/alt name for 2018.Added AQT for form 2022. AK 6/18/12  Added AQT, CSI,Alt name for 2025. AK 11/28/12. 4/2/15mn-added aqt for 2016r1. 2021-8-5 ak System generated def displayed as alt def.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}